Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 7/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27350904 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL10149550 | 0.94 | CYP3A4 (0.47) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL10149566 | 0.94 | CYP3A4 (0.36) | CYP3A4CYP2C9RIPK1 | |
| SCHEMBL10142570 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL15340432 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL10148602 | 0.93 | CYP3A4 (0.42) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL12833399 | 0.91 | CYP3A4 (0.34) | CYP3A4CYP2C9RIPK1 | |
| SCHEMBL12465034 | 0.91 | CYP3A4 (0.34) | CYP3A4CYP2C9RIPK1 | |
| SCHEMBL10149581 | 0.91 | CYP3A4 (0.34) | CYP3A4CYP2C9RIPK1 | |
| SCHEMBL12761486 | 0.91 | CYP3A4 (0.43) | CYP3A4CYP2C9BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375398-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-07-17 | — | — | US | disclosed |
| EP-3150608-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3150608-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2480552-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973013-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973013-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, MAVS | CYP3A4 4170/4885CYP2C9 4853/4885BTN3A1 2754/4885 |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, CDA | CYP3A4 355/4885CYP2C9 770/4885BTN3A1 4068/4885 |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, RNGTT, SLC29A1 | CYP3A4 426/4885CYP2C9 872/4885BTN3A1 4078/4885 |
| US-20250375398-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, MAVS | CYP3A4 4170/4885CYP2C9 4853/4885BTN3A1 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.